Cytek BioSciences EBIT

The latest EBIT for CTKB is $-42M as of June 2026. That compares with $-28M in the prior-year period — down 49.7% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Cytek BioSciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CTKB's EBIT moved from $-28M to $-42M — a 49.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cytek BioSciences's operating scale or balance-sheet position.

Against Healthcare companies, CTKB currently prints $-42M for EBIT, while the sector average sits near $23B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Cytek BioSciences's growth, margins, and balance sheet.

A EBIT figure of $-42M for CTKB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting CTKB's EBIT ($-42M), review year-over-year change from $-28M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.